The P2Y12 receptor as a therapeutic target in cardiovascular disease
about
sameAs
Combination antiplatelet therapy in patients with peripheral vascular bypass graftsClopidogrel's role in the management of atherosclerotic disease: a focus on acute coronary syndromesAspirin and clopidogrel resistance: an emerging clinical entityHigh post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndromePharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirinInvestigation on the antiplatelet activity of pyrrolo[3,2-c]pyridine-containing compoundsP2 receptors: new potential players in atherosclerosisPharmaceutical thrombosis prevention in cardiovascular disease.Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance.Characterization of a novel function-blocking antibody targeted against the platelet P2Y1 receptor.Uridine Triphosphate Thio Analogues Inhibit Platelet P2Y12 Receptor and Aggregation.Cangrelor for treatment of coronary thrombosis.Pharmacological antithrombotic adjuncts to percutaneous coronary intervention.Regulation of neuronal ion channels via P2Y receptors.The P2Y12 antagonists, 2-methylthioadenosine 5'-monophosphate triethylammonium salt and cangrelor (ARC69931MX), can inhibit human platelet aggregation through a Gi-independent increase in cAMP levels.Prasugrel: newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention.Antiplatelet therapy and vascular disease: an update.P2Y12 receptor: platelet thrombus formation and medical interventions.The discovery of a new class of synaptic transmitters in smooth muscle 50 years ago and amelioration of coronary artery thrombosis.Antiplatelet and anticoagulant therapy for atherothrombotic disease: the role of current and emerging agents.Role of New Antiplatelet Drugs on Cardiovascular Disease: Update on Cangrelor.Synthesis and biological evaluation of some dibenzofuran-piperazine derivatives.A point-of-care assay to measure platelet aggregation in patients taking clopidogrel.P2 receptors are involved in the mediation of motivation-related behavior.Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor.Effect of uridine 5'-triphosphate on mucin and lysozyme expression in human middle ear epithelial cells.Plasma ATP during exercise: possible role in regulation of coronary blood flow.A highly constrained cyclic (S,S)-CDC- peptide is a potent inhibitor of carotid artery thrombosis in rabbits.
P2860
Q28167367-BD199DC9-48FB-4AA8-86FB-D1C9DB9EC118Q28167896-774A63CB-19E4-449C-8B16-FBDF09FCD88BQ28194021-8A53F250-3B69-49C8-9980-5A4F08D20101Q28194081-87E4264D-F845-4898-93B4-D2F4D3C5E8FCQ28195019-0CF5AD85-DAB2-4FE7-9857-D10C291B47D7Q28195823-35715CEF-1CBE-40B7-9E0F-FDE627BF55E6Q34542194-046322B1-92A8-4ACD-9212-6169F8605C1DQ34581514-20D3585D-C5C4-45ED-A8DE-14B8E9F417A2Q34771381-FAB1C03F-7E61-4D06-997F-71967E0563BBQ35130686-FAD74E74-F0AA-4A3C-9A0F-9FCB06CA62B2Q36266153-BDE4991E-4850-46A4-ACAE-4093D7719655Q36440860-10753D21-F372-45C6-B5E0-398386C518DEQ36787291-CBF027A2-EA99-4C42-B8F6-2D9B017A7923Q37135473-1073BC75-DC6C-432F-A701-B0C4D13C7B85Q37269228-60B33F75-AAE7-4E7B-81FE-D2A6CA9FA4F6Q37486601-D47568E2-24D5-4B78-957F-1A84C942BB2BQ37838100-E28956BB-1419-45C4-B814-AA605F0C35B5Q38051192-F87C0153-2B1E-49EF-AD98-883841CB0A75Q38061149-C8290D7D-6E4E-4634-92EB-3631908A008CQ38101275-A510C6A0-A36E-4616-9C8E-E029073BDC90Q38974706-AB8F38C7-F938-429E-AA59-820966C26D64Q40307089-DA48F5DD-1D2C-407C-8A99-8EEB4F96D4F8Q40329955-12FBC061-2627-47C4-AA8A-2C8F8E81DC11Q40723755-AA3EBE0D-1747-453E-986E-B713AD46FB80Q43288118-B5BEBFEB-A3B2-428A-874C-4CB51E895A0AQ44434091-C50CC2A5-8A99-4CD2-9BCD-85878DBA89B1Q45162558-69BF7FC8-3243-4AEA-86E0-43ADC33E24EEQ45896173-B76D472B-9BE2-4A14-A4C5-65F00F7E9E93
P2860
The P2Y12 receptor as a therapeutic target in cardiovascular disease
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The P2Y12 receptor as a therapeutic target in cardiovascular disease
@ast
The P2Y12 receptor as a therapeutic target in cardiovascular disease
@en
The P2Y12 receptor as a therapeutic target in cardiovascular disease
@nl
type
label
The P2Y12 receptor as a therapeutic target in cardiovascular disease
@ast
The P2Y12 receptor as a therapeutic target in cardiovascular disease
@en
The P2Y12 receptor as a therapeutic target in cardiovascular disease
@nl
prefLabel
The P2Y12 receptor as a therapeutic target in cardiovascular disease
@ast
The P2Y12 receptor as a therapeutic target in cardiovascular disease
@en
The P2Y12 receptor as a therapeutic target in cardiovascular disease
@nl
P1433
P1476
The P2Y12 receptor as a therapeutic target in cardiovascular disease
@en
P2093
R F Storey
P304
P356
10.1080/09537100120058739
P407
P577
2001-06-01T00:00:00Z